Literature DB >> 9596383

Hepatitis C virus transmission dynamics in injection drug users.

H Hagan1.   

Abstract

Hepatitis C virus (HCV) presents several challenges to the development of prevention programs. HCV infection is persistent in up to 80% of cases, and viremic individuals may transmit infection to others. With 65-90% of injection drug users anti-HCV positive, a large reservoir of infection exists in most drug-injector populations. Studying the genetic variability of HCV infections could permit researchers to reconstruct chains of viral transmission in IDUs. However, the relationship of HCV to HIV epidemiology remains unclear and may depend on whether the proportions of infectious persons in the population are similar for both viruses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596383     DOI: 10.3109/10826089809062214

Source DB:  PubMed          Journal:  Subst Use Misuse        ISSN: 1082-6084            Impact factor:   2.164


  23 in total

1.  Vaccination could improve overall health in a high risk population.

Authors:  H Hagan
Journal:  West J Med       Date:  2000-01

2.  Hepatitis C among drug users: déjà vu all over again?

Authors:  D C Des Jarlais; A Schuchat
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

3.  Case-reporting of acute hepatitis B and C among injection drug users.

Authors:  Holly Hagan; Nadine Snyder; Eileen Hough; Tianji Yu; Shelly McKeirnan; Janice Boase; Jeffrey Duchin
Journal:  J Urban Health       Date:  2002-12       Impact factor: 3.671

4.  The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for hepatitis C infection.

Authors:  Elizabeth C Costenbader; William A Zule; Curtis M Coomes
Journal:  Drug Alcohol Depend       Date:  2007-02-22       Impact factor: 4.492

5.  How can hepatitis C be prevented in the long term?

Authors:  Pedro Mateu-Gelabert; Carla Treloar; Víctor Agulló Calatayud; Milagros Sandoval; Juan Carlos Valderrama Zurián; Lisa Maher; Tim Rhodes; Samuel R Friedman
Journal:  Int J Drug Policy       Date:  2007-07-24

6.  Self-reported hepatitis C virus antibody status and risk behavior in young injectors.

Authors:  Holly Hagan; Jennifer Campbell; Hanne Thiede; Steffanie Strathdee; Lawrence Ouellet; Farzana Kapadia; Sharon Hudson; Richard S Garfein
Journal:  Public Health Rep       Date:  2006 Nov-Dec       Impact factor: 2.792

Review 7.  Non-injection drug use and Hepatitis C Virus: a systematic review.

Authors:  Roberta Scheinmann; Holly Hagan; Corina Lelutiu-Weinberger; Rebecca Stern; Don C Des Jarlais; Peter L Flom; Shiela Strauss
Journal:  Drug Alcohol Depend       Date:  2006-12-15       Impact factor: 4.492

8.  A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C.

Authors:  Mary H Latka; Holly Hagan; Farzana Kapadia; Elizabeth T Golub; Sebastian Bonner; Jennifer V Campbell; Micaela H Coady; Richard S Garfein; Minya Pu; Dave L Thomas; Thelma K Thiel; Steffanie A Strathdee
Journal:  Am J Public Health       Date:  2008-04-01       Impact factor: 9.308

9.  The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.

Authors:  Xinyi Jiang; Hyun Jin Song; Wei Wang; Linda Henry; Lindsey M Childs-Kean; Vincent Lo Re; Haesuk Park
Journal:  J Manag Care Spec Pharm       Date:  2021-07

10.  Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.

Authors:  Benedikt Fischer; Emma Haydon; Jürgen Rehm; Mel Krajden; Jens Reimer
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.